The CJEU’s judgment on Gilead’s SPC for Truvada® is out now
G 1/18: New referral to the EPO’s Enlarged Board of Appeal
The objective technical problem should not be that much of a problem
Claim dismissed, counterclaim dismissed: Huge expense, no recompense
VESPA launches ‘epi Roundtable’ – sign-up now for August 28 to save your spot!
State of the art: Which art has to be considered?
Takeaways from the INGRES annual meeting
Laurastar and Innosteam Swiss working flat out
No further grounds for nullity of an SPC beyond Art. 140k of the Patent Act
Amlodipine / Valsartan: Controlling blood pressure while assessing obviousness
